Reviva Pharmaceuticals Holdings, Inc. (RVPH)
| Market Cap | 6.23M -89.7% |
| Revenue (ttm) | n/a |
| Net Income | -13.02M |
| EPS | -1.75 |
| Shares Out | 13.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,660 |
| Open | 0.4850 |
| Previous Close | 0.4782 |
| Day's Range | 0.4700 - 0.5300 |
| 52-Week Range | 0.2620 - 15.4000 |
| Beta | 0.48 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About RVPH
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of demen... [Read more]
Financial Performance
Financial StatementsNews
Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Fall 2026 Investor Conference
Brilaroxazine demonstrated robust, sustained efficacy and a superior safety profile in phase III trials for schizophrenia, with low relapse and discontinuation rates. Plans include a new proprietary formulation, extended patent life, and NDA filing by late 2028, with Nasdaq up-listing anticipated in 2027.
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartner...
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -
Reviva Pharmaceuticals Holdings Quarterly report: Q2 2026
Reviva Pharmaceuticals Holdings has published its Q2 2026 quarterly earnings report on August 12, 2026.
Reviva Pharmaceuticals Holdings Earnings release: Q2 2026
Reviva Pharmaceuticals Holdings released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Reviva Pharmaceuticals Holdings Transcript: Life Sciences Virtual Investor Forum
Brilaroxazine showed robust, durable efficacy and a favorable safety profile in phase III trials for schizophrenia, outperforming historical antipsychotics and addressing key unmet needs. A second phase III trial is planned, with NDA submission targeted for 2028 and potential exclusivity to 2046.
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Spring 2026 Investor Conference
Brilaroxazine showed robust, sustained efficacy and safety in phase III schizophrenia trials, with minimal relapse and superior differentiation versus current antipsychotics. A second confirmatory trial is planned, with NDA filing targeted for early 2028 and potential patent exclusivity to 2046.
Reviva Pharmaceuticals Holdings Transcript: A.G.P.'s Annual Virtual Healthcare Conference
Brilaroxazine is advancing to a pivotal phase III trial for schizophrenia, with a new formulation designed to extend patent life to 2046. Pending FDA feedback, the company aims to expand indications and regain Nasdaq compliance, supported by a strong financial position and major upcoming catalysts.
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Holdings Slides: Corporate presentation
Reviva Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 16, 2026.
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form ...
Reviva Pharmaceuticals Holdings Earnings release: Q1 2026
Reviva Pharmaceuticals Holdings released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Reviva Pharmaceuticals Holdings Quarterly report: Q1 2026
Reviva Pharmaceuticals Holdings has published its Q1 2026 quarterly earnings report on May 13, 2026.
Reviva Pharmaceuticals Holdings Transcript: Study update
Brilaroxazine is advancing to a second phase III trial in schizophrenia, with a new formulation aimed at extending patent life to 2046. FDA feedback on the formulation switch is expected mid-year, and the trial is set to start in Q3, leveraging strong prior data and a solid financial runway.
Reviva Pharmaceuticals Holdings Earnings release: Q4 2025
Reviva Pharmaceuticals Holdings released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
Reviva Pharmaceuticals Holdings Annual report: Q4 2025
Reviva Pharmaceuticals Holdings has published its Q4 2025 annual report on March 30, 2026.
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia –
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...
Reviva Pharmaceuticals Holdings Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Brilaroxazine showed robust, sustained efficacy and a favorable safety profile in schizophrenia, with significant improvements in negative symptoms and low relapse rates. An additional phase 3 trial, required by the FDA, is set to begin soon, targeting NDA submission in late 2027.
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the t...
Reviva Pharmaceuticals Holdings Slides: Corporate presentation
Reviva Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on December 23, 2025.
Reviva Pharmaceuticals Holdings Proxy statement: Proxy Filing
Reviva Pharmaceuticals Holdings filed a proxy statement on December 5, 2025, providing details for shareholder voting and corporate governance matters.